m+Medelevator.RU
← Поиск публикаций
Frontiers in immunology · 2026

Laptm4a mediates renal ischemia-reperfusion injury by regulating the UNC5B-AKT/mTOR signaling pathway.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Ma Xiaoxiong, Chen Zhan, Wang Tianyu, Chen Zhongbao, Qiu Tao, Zhou Jiangqiao

Аннотация

INTRODUCTION: Renal ischemia-reperfusion injury (IRI) is a major cause of acute kidney injury (AKI), but specific therapeutic targets are lacking.Lysosomal Protein Transmembrane 4A (LAPTM4A), a four transmembrane-spanning protein mainly localized in endosomes and lysosomes,however, its pathological role in AKI remains unexplored.

METHODS: To investigate the impact of LAPTM4A on renal IRI, we developed an in vivo renal IRI model utilizing LAPTM4A knockout mice, alongside an in vitro hypoxia-reperfusion(H/R) model employing shRNA to knockdown LAPTM4A in HK2 cell. A comprehensive suite of methodologies, including Western blotting, qPCR, CCK-8 assay, LDH assay, TUNEL assay, ELISA, and histopathological analysis, was employed to evaluate cell proliferation, apoptosis, and inflammatory cytokine levels.

RESULTS: We found that the expression of Laptm4a was upregulated in kidney of renal IRI mice and HK2 cell induced by hypoxia-reoxygenation(H/R). Knockout of Laptm4a improved renal function , attenuated tubular injury and reduced inflammatory cell infiltration and apoptosis, whereas overexpression exacerbated the injury.Mechanistically Laptm4a exacerbated renal IRI through suppression of the UNC5B-AKT-mTOR protective signaling pathway.

CONCLUSIONS: Our findings suggest that Laptm4a exacerbates inflammation and apoptosis by inhibiting the UNC5B-PI3K-AKT signaling pathway. This study provides a novel elucidation of the role of Laptm4a as a critical positive regulator of IRI, offering preliminary preclinical insights that may inform future investigations into therapeutic strategies.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты